Related Experiment Video

Updated: Aug 14, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

[Levosimendan: a new strategy in the treatment of heart failure]

Octavio González-Chon1, Sandra María del Carmen García López, Marco Alejandro Chacón Mercado

  • 1Jefe de la Unidad Coronaria, Fundación Clínica Médica Sur. Tlalpan 41050, México, DF. ogchon@medicasur.org.mx

Archivos De Cardiologia De Mexico
|December 22, 2005
PubMed

Insights

Levosimendan, a novel calcium sensitizer, offers a safe and effective treatment for heart failure by enhancing contractility and vasodilation. This drug presents a valuable alternative for patients requiring intravenous support for ventricular failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) is a prevalent condition with limited treatment options.
  • Traditional CHF therapies (diuretics, digitalis, inotropics) carry significant adverse effects, including arrhythmia and mortality.
  • Novel therapeutic approaches are needed to improve outcomes for heart failure patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of levosimendan as a treatment for heart failure.
  • To explore the mechanisms of action of levosimendan in enhancing cardiac function.

Main Methods:

  • Review of clinical studies investigating levosimendan in acute and chronic heart failure.
  • Analysis of levosimendan's pharmacological profile, including its effects on myocardial contractility and vasodilation.
  • Assessment of safety data regarding adverse events associated with levosimendan use.

Main Results:

  • Levosimendan enhances myocardial contractility without increasing intracellular calcium levels.
  • The drug exhibits vasodilatory effects through K(ATP) channel activation.
  • Studies demonstrate a favorable efficiency and safety profile across diverse patient populations and clinical scenarios.

Conclusions:

  • Levosimendan represents a significant advancement in heart failure pharmacotherapy.
  • Its dual mechanism of action (inotropic and vasodilatory) provides a therapeutic advantage.
  • Levosimendan is a safe and effective intravenous option for patients with acute or chronic ventricular failure.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.